中藥調(diào)控NLRP3炎癥小體改善心肌纖維化的研究進展
中圖分類號R965;R285 文獻標志碼A 文章編號 1001-0408(2025)08-1008-05
DOI 10.6039/j.issn.1001-0408.2025.08.21
Research progress on the improvement of myocardial fibrosis by traditional Chinese medicine through regulation of NLRP3 inflammasome
ZHANG Rui',YAN Jingshun',JIA Fuyun',JIA Kexin',LIU Chenyang',LIU ,LI ,XU Qiang2(1. Graduate SchoolTianjin University of Traditional Chinese Medicine, Tianjin 3016l7, China;2.Dept.of Cardiology,the Second Afiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China)
ABSTRACTMyocardialfibrosis(MF),characterizedbydecreased cardiacfunction and myocardial compliance,isa pathologicalprocessandaprogressionfactorinvariouscardiovasculardiseasesThenucleotide-bindingdomainleucine-richrepeat and pyrindomain-containingreceptor 3(NLRP3)inflammasome iscloselyrelated tothedevelopmentof MF.Recent studies have shownthattraditionalChinesemedicine(TCM)canregulatetheNRPinflammasometoaleviateMFBasedonthisthisarticle systematicallysummarizestheresearchprogressonthemechanismsbywhichTCMregulatestheNLRP3inflammasometo improve MF.It is foundthatactiveingredientsof TCM,suchasalkaloids(lycorine,vincristine,bufalin),saponins(astragaloside IV, diosgenin, ginsenoside ),terpenoids(celastrol,oridonin),and phenols(polydatin,curcumin,phloridzin) as well as TCM formulas(Zhachong shisanwei pillZhilong huoxuetongyucapsules,Luqiformula)caninhibit theactivationof the NLRP3 inflammasome, thereby suppressing the release of inflammatory factors such as interleukin- 1β and IL-18, reducing inflammatory damagetomyocardiatissuealeviatingexcessivedepositionoftheextracellulaatrixandthusexertingtheeecofiproving MF.
KEYWORDSactivecomponentof TCM;TCMformula; myocardialfibrosis;NLRP3inflammasome;mechanismof action
心肌纖維化(myocardialfibrosis,MF)是由中、重度冠狀動脈粥樣硬化性狹窄引起心肌纖維持續(xù)性和(或)反復加重的缺血缺氧所導致的心肌纖維組織增生。(剩余12705字)
- 藥品臨床綜合評價主題選指南...
- 我國公立中醫(yī)類醫(yī)院中藥師(士)...
- 患者參與藥物監(jiān)管的國際經(jīng)驗與啟...
- 基于多準則決策分析的縣域醫(yī)共體...
- 烏司他丁改善順鉑致心肌損傷的作...
- 類葉牡丹關節(jié)注射液治療類風濕性...
- 異鼠李素通過上調(diào)SLC25A2...
- 布美他尼對慢性阻塞性肺疾病模型...
- 伊魯阿克治療ALK陽性晚期NS...
- 羅哌卡因聯(lián)合羥考酮用于髖關節(jié)置...
- 替爾泊肽不良事件信號挖掘與分析...
- 腸內(nèi)免疫微生態(tài)營養(yǎng)聯(lián)合 ω-3...
- 雌二醇片/雌二醇地屈孕酮片聯(lián)合...
- 環(huán)泊酚復合局麻用于老年患者痔瘡...
- 過敏性紫癜性腎炎患兒他克莫司血...
- 1例熱紫鏈霉菌肺炎診治過程及文...
- 克拉霉素潛在不良藥物相互作用分...
- 藥物防治糖皮質(zhì)激素性骨質(zhì)疏松的...
- 抗VEGF藥物治療糖尿病性黃斑...
- 鈣離子通道調(diào)節(jié)劑治療糖尿病周圍...
- 中藥調(diào)控NLRP3炎癥小體改善...
- 生理藥代動力學模型在EGFR-...
- 中藥調(diào)控PI3K/Akt信號通...